Optiscan Imaging Limited

Equities

OIL

AU000000OIL4

Advanced Medical Equipment & Technology

Market Closed - Australian S.E. Other stock markets 09:55:31 2024-04-23 pm EDT			5-day change	1st Jan Change
0.086 ^AUD	+4.88%		-10.42%	+2.38%

Mar. 21	Optiscan Imaging Receives More Than AU$670,000 as R&D Tax Rebate	MT
Feb. 22	Optiscan Imaging Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Optiscan Imaging : Appointment of Prof. Camile Farah as New CEO & Managing Director

January 16, 2022 at 06:25 pm EST

We are pleased to announce the appointment of our new CEO & Managing Director, Professor Camile Farah MBA PhD FAIM. Prof Farah brings over 25 years of medical, executive and board-level experience to Optiscan that will accelerate our growth and broaden our footprint globally.

Read more:
https://lnkd.in/gtrNFrRZ
https://lnkd.in/gBeaExrF

Attachments

Original Link
Original Document
Permalink

Disclaimer

Optiscan Imaging Limited published this content on 17 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 January 2022 23:24:05 UTC.

Latest news about Optiscan Imaging Limited

Optiscan Imaging Receives More Than AU$670,000 as R&D Tax Rebate	Mar. 20	MT
Optiscan Imaging Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 22	CI
Optiscan Imaging Secures AU$3 Million Research Grant for Endomicroscope Device; Shares Rise 8%	Feb. 12	MT
Optiscan Imaging Appoints COO	23-10-23	MT
Optiscan Imaging Limited Appoints Brendan Fafiani to the Role of Chief Operating Officer, Effective 6 November 2023	23-10-22	CI
Cancer Images from Optiscan's Platform Comparable With Conventional Histology Analysis, Study Says	23-09-20	MT
Optiscan Imaging Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Optiscan Imaging Completes Key Milestone for Telepathology Project	23-08-15	MT
Optiscan Imaging Establishes New Commercial Operation in the US	23-04-03	MT
Optiscan Imaging Confirms High Diagnostic Rate of Imaging Device	23-03-14	MT
Optiscan Imaging Receives US FDA Feedback for Oral Imaging Product	23-03-02	MT
Optiscan Imaging Limited Intends to Pursue De Novo Pathway for InVivage	23-03-01	CI
Optiscan Imaging Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-26	CI
Optiscan Imaging Limited Announces Partnership with Prolucid Technologies to Develop AI Algorithms	23-01-29	CI
Optiscan Imaging Proposes Issuance of 6 Million Securities	22-10-25	MT
Optiscan Imaging Acquiring Clinical Datasets from Managing Director; Shares Rise 4%	22-10-24	MT
Optiscan Imaging Secures R&D Tax Rebate	22-10-24	MT
Optiscan Imaging Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-31	CI
Optiscan Imaging Files US FDA Application for Oral Tissue Imaging Device	22-08-22	MT
Optiscan Submits FDA 510(k) Application for InVivage Device	22-08-21	CI
Optiscan Imaging Limited Announces Strategic Distribution Partnership - Additional Information	22-06-27	CI
Optiscan Imaging Appoints China Distributor for Research, Preclinical Device	22-06-27	MT
Optiscan Imaging Limited Announces Strategic Distribution Partner for China	22-06-26	CI
Optiscan Imaging Limited Appointment of Sean Gardiner as Non-Executive Director	22-06-14	CI
Optiscan Imaging Limited Reports Earnings Results for the Half Year Ended December 31, 2021	22-02-24	CI

Chart Optiscan Imaging Limited

Duration

Period

More charts

Company Profile

Optiscan Imaging Limited is an Australia-based company, which is engaged in the development, manufacturing and commercialization of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. The Companyâs technology enables real-time, non-destructive, three-dimensional (3D), in-vivo imaging at the single-cell level. It provides real-time microscopic imaging tools to healthcare providers and researchers to enable the early detection and management of disease. Its InVivage device is developed for clinical use in oral cancer and other cancer applications. Its Fluorescence In Vivo Endomicroscopy (FIVE2) also known as ViewnVivo system, is a hand-held, confocal microscope designed for pre-clinical use. This device is targeted for use by universities and medical research institutions to explore potential applications of the technology through laboratory testing of tissue samples.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-28 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
OPTISCAN IMAGING LIMITED	+2.38%	46.61M
THERMO FISHER SCIENTIFIC	+7.71%	220B
DANAHER CORPORATION	+6.25%	185B
INTUITIVE SURGICAL, INC.	+10.60%	133B
BOSTON SCIENTIFIC CORPORATION	+26.73%	107B
SIEMENS HEALTHINEERS AG	-0.57%	62.91B
EDWARDS LIFESCIENCES CORPORATION	+15.42%	53.34B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-1.89%	47.71B
AGILENT TECHNOLOGIES, INC.	-1.91%	40.29B
GE HEALTHCARE TECHNOLOGIES INC.	+11.16%	39.57B

Other Advanced Medical Equipment & Technology